Lung cancer genomic signatures

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1673-1691

  Agulló Ortuño, M Teresa ^a   López Ríos, Fernando ^b   Paz Ares, Luis ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Hospital Universitario Madrid Sanchinarro   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Genomic signatures; High throughput technologies; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DUAL SPECIFICITY PHOSPHATASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; PEMETREXED; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; VASCULOTROPIN INHIBITOR; VORINOSTAT;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER RESISTANCE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ANALYSIS; GENOMIC IN SITU HYBRIDIZATION; GENOMICS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN GENOME; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; NORTHERN BLOTTING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 77958192609     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f1900e     Document Type: Article

References (179)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442. (Pubitemid 44875937)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-249.
3. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. (Pubitemid 32165345)
4. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-1351. (Pubitemid 32173090)
5. Dressman HK, Bild A, Garst J, et al. Genomic signatures in non-smallcell lung cancer: targeting the targeted therapies. Curr Oncol Rep 2006;8:252-257. (Pubitemid 43970976)
6. Garrett-Mayer E, Parmigiani G, Zhong X, et al. Cross-study validation and combined analysis of gene expression microarray data. Biostatistics 2008;9:333-354. (Pubitemid 351438557)
7. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, et al. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 2004;10:2922-2927. (Pubitemid 38619666)
8. Segal E, Friedman N, Kaminski N, et al. From signatures to models: understanding cancer using microarrays. Nat Genet 2005;37(Suppl): S38-S45. (Pubitemid 40770402)
9. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007;96:1155-1158. (Pubitemid 46625063)
10. Allison DB, Cui X, Page GP, et al. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006;7:55-65. (Pubitemid 41828948)
11. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795. (Pubitemid 33115977)
12. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789. (Pubitemid 33115976)
13. Beer DG, Kardia SLR, Huang C-C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med 2002;8:816-824.
14. Jiang H, Deng Y, Chen HS, et al. Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinformatics 2004;5:81. Available at: http://www.biomedcentral. com/1471-2105/5/81. (Pubitemid 40195422)
15. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-3226. (Pubitemid 46211346)
16. Pawitan Y, Michiels S, Koscielny S, et al. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005;21:3017-3024. (Pubitemid 40916427)
17. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365: 488-492. (Pubitemid 40215731)
18. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-157.
19. Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet 2007;8:601-609. (Pubitemid 47077277)
20. Dobbin KK, Beer DG, Meyerson M, et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005;11:565-572. (Pubitemid 40116881)
21. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival1. Cancer Res 2002;62:3005-3008. (Pubitemid 34602385)
22. Nacht M, Dracheva T, Gao Y, et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA 2001;98:15203-15208. (Pubitemid 34013992)
23. Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002;62:3971-3979. (Pubitemid 34791062)
24. Fujii T, Dracheva T, Player A, et al. A preliminary transcriptome map of non-small cell lung cancer. Cancer Res 2002;62:3340-3346. (Pubitemid 34651374)
25. Wang K-k, Liu N, Radulovich N, et al. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 2002;21:7598-7604. (Pubitemid 35305588)
26. Pedersen N, Mortensen S, Sorensen SB, et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003; 63:1943-1953. (Pubitemid 36460862)
27. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003;9:4695-4704. (Pubitemid 37323271)
28. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-2205. (Pubitemid 36539569)
29. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-1688. (Pubitemid 46622139)
30. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090. (Pubitemid 46631412)
31. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
32. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-356. (Pubitemid 351212390)
33. Kuner R, Muley T, Meister M, et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 2009;63:32-38.
34. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
35. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007;8:93-103. (Pubitemid 46122839)
36. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773. (Pubitemid 40292988)
37. Liu Z, Sall A, Yang D. MicroRNA: an emerging therapeutic target and intervention tool. Int J Mol Sci 2008;9:978-999. (Pubitemid 351948835)
38. Backes C, Meese E, Lenhof HP, et al. A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res 2010;38:4476-4486.
39. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756. (Pubitemid 38697282)
40. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647. (Pubitemid 40343076)
41. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833. (Pubitemid 40839734)
42. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008;452:1-10.
43. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623-631.
44. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004. (Pubitemid 38327724)
45. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007;117: 2059-2066.
46. Sevignani C, Calin GA, Nnadi SC, et al. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA 2007;104:8017-8022. (Pubitemid 47185868)
47. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
48. Manikandan J, Aarthi JJ, Kumar SD, et al. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation 2008;2:330-334.
49. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12. (Pubitemid 46096921)
50. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39:673-677. (Pubitemid 46676103)
51. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198. (Pubitemid 43357945)
52. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469. (Pubitemid 351501813)
53. Liang Y. An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics 2008;1:61. Available at: http://www.biomedcentral.com/1755-8794/1/61.
54. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-2037.
55. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
56. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007;67:7713-7722. (Pubitemid 47281364)
57. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-1423. (Pubitemid 46383365)
58. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:11111-11116. (Pubitemid 350248533)
59. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
60. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-9632. (Pubitemid 41541436)
61. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-843.
62. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69:5776-5783.
63. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-1307. (Pubitemid 47176893)
64. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26: 731-743. (Pubitemid 46856247)
65. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-1593. (Pubitemid 47327945)
66. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261. (Pubitemid 43271657)
67. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118:2600-2608. (Pubitemid 351949787)
68. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008;28:2167-2174. (Pubitemid 351429964)
69. Chen JJW, Peck K, Hong T-M, et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001;61:5223-5230. (Pubitemid 32681557)
70. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nature Genet 2003;33:49-54. (Pubitemid 36068681)
71. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22:811-819. (Pubitemid 41103592)
72. Sun Z, Yang P, Aubry MC, et al. Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol Cancer 2004;3:35. Available at: http://www.molecular-cancer.com/content/3/1/35. (Pubitemid 40230537)
73. Takada M, Tada M, Tamoto E, et al. Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. J Surg Res 2004;122:61-69. (Pubitemid 39441234)
74. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004;23:5360-5370. (Pubitemid 39005811)
75. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in earlystage non-small cell lung cancer. Cancer Res 2004;64:5564-5569. (Pubitemid 39095550)
76. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005;65:1778-1782. (Pubitemid 40478604)
77. Xi L, Lyons-Weiler J, Coello MC, et al. Prediction of lymph node metastasis by analysis of gene expression profiles in primary lung adenocarcinomas. Clin Cancer Res 2005;11:4128-4135. (Pubitemid 40791577)
78. Inamura K, Fujiwara T, Hoshida Y, et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005;24:7105-7113. (Pubitemid 41573639)
79. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580. (Pubitemid 44200650)
80. Guo L, Ma Y, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006;12: 3344-3354. (Pubitemid 43910878)
81. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467. (Pubitemid 46026444)
82. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-7472. (Pubitemid 44289200)
83. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
84. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non-small-cell lung cancer. J Clin Oncol 2007;25: 5562-5569.
85. Larsen JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007;28:760-766. (Pubitemid 46523374)
86. Larsen JE, Pavey SJ, Passmore LH, et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007;13: 2946-2954. (Pubitemid 46849569)
87. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117:3436-3444. (Pubitemid 350096999)
88. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007;2:e1129. (Pubitemid 351594028)
89. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-1269. (Pubitemid 47299904)
90. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008;14:4794-4799.
91. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008;26:877-883. (Pubitemid 351398079)
92. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008;3:e1651. (Pubitemid 351865456)
93. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008;14:5565-5570.
94. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-827.
95. Vicent S, Luis-Ravelo D, Anton I, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008;68:2275-2285. (Pubitemid 351521801)
96. Landemaine T, Jackson A, Bellahcene A, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res 2008;68:6092-6099.
97. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15:284-290.
98. Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA 2009;106:2824-2828.
99. Broet P, Camilleri-Broet S, Zhang S, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 2009;69:1055-1062.
100. Hsu YC, Yuan S, Chen HY, et al. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res2009;15:7309-7315.
101. Showe MK, Vachani A, Kossenkov AV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202-9210.
102. Tomida S, Takeuchi T, Shimada Y, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009;27:2793-2799.
103. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-511. (Pubitemid 34920572)
104. Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest 2003;123(Suppl 1):72S-82S. (Pubitemid 36135704)
105. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006;103:5923-5928.
106. Guo NL, Wan YW, Tosun K, et al. Confirmation of gene expressionbased prediction of survival in non-small cell lung cancer. Clin Cancer Res 2008;14:8213-8220.
107. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
108. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300. (Pubitemid 44706932)
109. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357. (Pubitemid 43128862)
110. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323-334. (Pubitemid 36962931)
111. Huang ES, Black EP, Dressman H, et al. Gene expression phenotypes of oncogenic signaling pathways. Cell Cycle 2003;2:415-417.
112. Black EP, Huang E, Dressman H, et al. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 2003;63:3716-3723. (Pubitemid 36793057)
113. Segal E, Friedman N, Koller D, et al. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004; 36:1090-1098. (Pubitemid 41184471)
114. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101: 9309-9314. (Pubitemid 38812872)
115. McMurray HR, Sampson ER, Compitello G, et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 2008;453:1112-1116. (Pubitemid 351871734)
116. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
117. Lee S, Kang J, Cho M, et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009;34:161-172.
118. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55. (Pubitemid 40070939)
119. Ranganathan P, Agrawal A, Bhushan R, et al. Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. BMC Genomics 2007;8:98. Available at: http://www. biomedcentral.com/1471-2164/8/98. (Pubitemid 46696037)
120. Jeon HS, Dracheva T, Yang SH, et al. SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 2008;68:9686-9692.
121. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol 2010;5:417-419.
122. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 2010;46:1232-1240.
123. Borczuk AC, Kim HK, Yegen HA, et al. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005;172:729-737.
124. Borczuk AC, Papanikolaou N, Toonkel RL, et al. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2008;27:557-564.
125. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-137. (Pubitemid 39485685)
126. Oshita F, Ikehara M, Sekiyama A, et al. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer. J Exp Ther Oncol 2004;4:155-160. (Pubitemid 39079052)
127. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-3043. (Pubitemid 40045258)
128. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11: 8686-8698. (Pubitemid 43005918)
129. Gemma A, Li C, Sugiyama Y, et al. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer 2006;6:174. Available at: http://www.biomedcentral.com/1471-2407/6/174. (Pubitemid 44202807)
130. Coldren CD, Helfrich BA, Witta SE, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006;4:521-528. (Pubitemid 44341362)
131. Gyorffy B, Surowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-1712. (Pubitemid 43376433)
132. Balko JM, Potti A, Saunders C, et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 2006;7:289. Available at: http://www.biomedcentral.com/1471-2164/7/289. (Pubitemid 44823100)
133. McDermott U, Sharma SV, Dowell L, et al. Identification of genotypecorrelated sensitivity to selective kinase inhibitors by using highthroughput tumor cell line profiling. Proc Natl Acad Sci USA 2007; 104:19936-19941.
134. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007;25:4350-4357.
135. Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7:1923-1930.
136. Minna JD, Girard L, Xie Y. Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 2007;25:4329-4336. (Pubitemid 350013833)
137. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244. (Pubitemid 30132190)
138. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-823.
139. Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010;29:2346-2356.
140. Rosell R, Felip E, Paz-Ares L. How could pharmacogenomics help improve patient survival? Lung Cancer 2007;57(Suppl 2):S35-S41. (Pubitemid 47188081)
141. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
142. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007;67:2045-2075.
143. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25: 2747-2754. (Pubitemid 47123183)
144. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
145. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867-3874.
146. Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res 2009; 315:557-571.
147. Naxerova K, Bult CJ, Peaston A, et al. Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers. Genome Biol 2008;9:R108. Available at: http://genomebiology.com/2008/9/ 7/R108.
148. Hassan KA, Chen G, Kalemkerian GP, et al. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 2009;15:6386-6390.
149. Stevenson M, Mostertz W, Acharya C, et al. Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma. Clin Cancer Res 2009;15:7553-7561.
150. Borczuk AC, Gorenstein L, Walter KL, et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003;163:1949-1960. (Pubitemid 37310025)
151. Shen J, Behrens C, Wistuba, II, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 2006;66:11194-11206. (Pubitemid 46009947)
152. Pan KH, Lih CJ, Cohen SN. Effects of threshold choice on biological conclusions reached during analysis of gene expression by DNA microarrays. Proc Natl Acad Sci USA 2005;102:8961-8965.
153. Krafft AE, Duncan BW, Bijwaard KE, et al. Optimization of the isolation and amplification of rna from formalin-fixed, paraffin-embedded tissue: the Armed Forces Institute of Pathology experience and literature review. Mol Diagn 1997;2:217-230.
154. Finke J, Fritzen R, Ternes P, et al. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffinembedded tissues by PCR. Biotechniques 1993;14:448-453. (Pubitemid 23086133)
155. Park YN, Abe K, Li H, et al. Detection of hepatitis C virus RNA using ligation-dependent polymerase chain reaction in formalin-fixed, paraffin-embedded liver tissues. Am J Pathol 1996;149:1485-1491. (Pubitemid 26363955)
156. Jackson DP, Quirke P, Lewis F, et al. Detection of measles virus RNA in paraffin-embedded tissue. Lancet 1989;1:1391. (Pubitemid 19151985)
157. Stanta G, Schneider C. RNA extracted from paraffin-embedded human tissues is amenable to analysis by PCR amplification. Biotechniques 1991;11:304, 306, 308.
158. Linton KM, Hey Y, Saunders E, et al. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer 2008; 98:1403-1414. (Pubitemid 351543581)
159. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-429. (Pubitemid 32158605)
160. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalinfixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007;7:36. (Pubitemid 47065165)
161. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007;9:443-454. (Pubitemid 46799988)
162. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935. (Pubitemid 44497995)
163. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550. (Pubitemid 41528093)
164. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898. (Pubitemid 350231325)
165. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
166. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007;6:70.
167. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-622. (Pubitemid 351601203)
168. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-763. (Pubitemid 351483367)
169. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-642. (Pubitemid 351483366)
170. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26: 856-862. (Pubitemid 351398076)
171. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008;83:477-484. (Pubitemid 351272637)
172. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008;8: 129-138. (Pubitemid 351411549)
173. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566. (Pubitemid 47206930)
174. Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, et al. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol 2008;3:S107-S112.
175. Anguiano A, Nevins JR, Potti A. Toward the individualization of lung cancer therapy. Cancer 2008;113(Suppl 7):1760-1767.
176. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24:1115-1122. (Pubitemid 44359723)
177. Lynch TJ, Bonomi PD, Butts C, et al. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 2007;13: s4583-s4588. (Pubitemid 47219729)
178. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746. (Pubitemid 47123182)
179. Herbst RS, Lippman SM. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med 2007;356:76-78. (Pubitemid 46041757)